Sep 05, 2019 - It’s rejected a pair of drugs in the last six months.
Sep 05, 2019 - Endo (ENDP) receives an FDA approval for the generic equivalent of Swedish Orphan Biovitrum's Orfadin.
Sep 05, 2019 - AstraZeneca's (AZN) Tagrisso gets a marketing approval in China for the first-line treatment of advanced or metastatic non-small cell lung cancer in patients with tumors having EGFR mutations.
Sep 10, 2019 - The Dow is expected to maintain its current momentum for the rest of this month and further due to two immediate catalysts.
Sep 11, 2019 - We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.
Sep 13, 2019 - Roche's (RHHBY) new fixed-dose combination of Perjeta and Herceptin meets the primary endpoint in the phase III study for treating patients with HER2-positive early breast cancer.
Sep 17, 2019 - J&J's (JNJ) sBLA seeking approval for Tremfya for active psoriatic arthritis is based on data from the phase III DISCOVER 1 and 2 studies.
Sep 23, 2019 - Glaxo's (GSK) SLE drug Benlysta gets a favorable CHMP opinion that recommends an approval for intravenous formulation in pediatric patients.
Sep 23, 2019 - Companies In The News Are: MDR, MRK, NFLX, XLNX
Sep 25, 2019 - Bristol-Myers (BMY) receives a positive response from the CHMP for a four-week dosing option with Opdivo as an adjuvant treatment of adult patients with melanoma.